-+ 0.00%
-+ 0.00%
-+ 0.00%

*Minerva: FDA Interactions Continue for Complete Response Letter to NDA for Roluperidone for Negative Symptoms in Patients With Schizophrenia

Dow Jones·05/13/2025 11:38:00

Please log in to view news